1 / 71

TRALI: It’s Not Just For Blood Bankers Anymore

TRALI: It’s Not Just For Blood Bankers Anymore. Norman D. Means, MD, FCAP Blood Bank of Alaska. TRALI. What is it?. Transfusion-Related Acute Lung Injury. First described by Popovsky , Abel and Moore in 1983 Am Rev Resp Dis 1983;128:185-9 Acute Pulmonary Edema Respiratory Distress

amir-woods
Download Presentation

TRALI: It’s Not Just For Blood Bankers Anymore

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. TRALI: It’s Not Just For Blood Bankers Anymore Norman D. Means, MD, FCAP Blood Bank of Alaska

  2. TRALI What is it?

  3. Transfusion-Related Acute Lung Injury • First described by Popovsky , Abel and Moore in 1983 Am Rev RespDis 1983;128:185-9 • Acute Pulmonary Edema • Respiratory Distress • Hypoxemia • Hypotension • Fever • In the setting of a recent transfusion

  4. History • Case reports as long ago as 1951 • “Noncardiogenic edema” • “Allergic pulmonary edema” • “Hypersensitivity reaction” • “Leukoagglutinin transfusion reaction”

  5. History • TRALI is a difficult diagnosis to make, since there are often confounding underlying medical conditions that tend to obscure the diagnosis • TRALI is one subset of Acute Lung Injury • Spectrum of disorders

  6. Acute Lung Injury • Spectrum of injury • Acute Respiratory Distress Syndrome (ARDS) is most severe form • Many potential causes, including many causes which are treated by transfusion • Up to 40% of acutely ill, actively bleeding patients will develop ALI • Pulmonary edema may develop simultaneously

  7. ALI/ARDS Other possible causes of ALI/ARDS • Sepsis • Trauma • Aspiration • Shock • others

  8. Acute Lung Injury • ARDS Mortality 30 – 40% • TRALI Mortality 6 – 12%

  9. Consensus conferences • North American-European Consensus Conference on ARDS (1994) • NHLBI Working Group (2002) • Canadian Consensus Conference (2004)

  10. North American European CC Acute Lung Injury definition: • Acute hypoxemia • PaO2/FiO2 <300 mm Hg • Pulmonary edema on frontal CXR • Pulmonary artery occlusion pressure <18 mm HG or no evidence of left atrial hypertension

  11. NHLBI WG /Canadian CC Defined TRALI • Adopted NAECC definition of ALI • TRALI if 6 hours since transfusion • Risk factors for ALI • Canadian: “possible TRALI” • NHLBI: interpret time course

  12. Why is TRALI suddenly so important?

  13. Transfusion-associated fatalities reported to the FDA 1990-1998 Source: Lee, JH Workshop on Bacterial Contamination of Platelets, 9/24/99; adapted from Menitove, JE Complications of Transfusion (p 1617), in Clinical Laboratory Medicine, 2nd Ed. (2001) , McClatchey, KD, ed.

  14. Transfusion-associated fatalities reported to the FDA 2005-2006 • Cases • 6 Source: Fatalities reported to the FDA following blood collection and transfusion (2005-2006); from http://www.fda.gov/cber/blood/fatal0506.htm

  15. Differential Diagnosis of TRALI

  16. TACO Transfusion-Associated Circulatory Overload

  17. TACO • The most common transfusion reaction • 1-8% of post surgical patients requiring transfusion • Age > 60 may develop with only a single unit of pRBC • Dyspnea, orthopnea, elevated BP, pedal edema, crackles, tachycardia, infiltrates • Elevated BNP

  18. Anaphylactic Reactions • Bronchospasm • Wheezing • Laryngeal edema • Urticaria/Erythema • Hypotension • Rapid onset after start of transfusion • IgA deficiency

  19. Transfusion-Associated Sepsis • Fever • Hypotension • Shock • Rapid onset • Bacteria present • Platelets most at risk

  20. Pathophysiology of TRALI • Traditional model (antibody transfer) • Transfer of biologic response modifiers

  21. Traditional Model • Passive transfer of antibody via transfusion • HLA Class II, HNA, HLA Class I antibodies • Sensitized donors • Multiparous women • Organ and tissue transplant recipients • Previously transfused blood donors

  22. Traditional Model • Bray, et al (2004) • 308 randomly selected units of plts, pRBC, FFP, cryoprecipitate • Overall 22% of units had HLA antibodies • FFP 29% • Cryo 24% Hum Immunol 2004;65:240-4

  23. Traditional Model • Why don’t we see more TRALI? • Antigen-antibody pairing • Threshold concentration of antibodies • Preexisting endothelial “priming” may potentiate response

  24. Bioactive Response Modifier Model • Accumulation of IL-6, IL-8, PAF, IFN-γ, TNF-α, NO, bioactive lipids • Transfusion leads to activation of inflammatory cascade (NO→vasoconstriction) • Damage to alveolar capillaries or increased hydrostatic pressure • Pulmonary Edema

  25. Bioactive Response Modifier Model • These bioactive agents have been shown to accumulate in stored blood products over time. • Levels may rise high enough to “prime” neutrophils or endothelial cells • Some evidence that these may rarely trigger TRALI directly.

  26. Pathophysiology of TRALI • Probably all of these models have some role to play in the causation of TRALI • Other causes may emerge

  27. Pathophysiology of TRALI • End result is damage to the pulmonary capillary endothelium • Neutrophil-induced damage • Activated neutrophils • express HLA Class II and HNA antigens • Activated pulmonary endothelium • express HLA Class II antigens

  28. Pathophysiology of TRALI • Activated neutrophils • Response to various priming agents • PAF, TNF-α, IL-8, GM-CSF, IFN-γ, LPS, infectious agents • Anatomic and physiologic changes • Stiffening (actin polymerization) • Adhesivity (β2integrins, selectins) • Clustering of surface receptors (FcγRIIa, β2integrins) • Release of toxic granule enzymes • Formation of NADPH oxidase → Reactive oxygen species

  29. Pathophysiology of TRALI • Activated neutrophils • Activation may be triggered by a number of events • Infection • Cardiovascular disease • Leukemia • Recent surgery • Others (trauma?, hemorrhage?) • Mechanical sequestration and aggregation in pulmonary microvasculature

  30. Pathophysiology of TRALI • Activated endothelium • Increased adhesivity (selectins, ICAM-1) • Promotes priming of “captured” neutrophils • Interaction of activated endothelium and neutrophils leads to endothelial damage/TRALI • Platelet activation • Increased neutrophil aggregation • Complement activation • Role unclear

  31. Pathophysiology of TRALI • Neutrophil specific antibodies • HNA, HLA Class II, and HLA Class I • Some are strong enough to trigger TRALI alone • Presence of leukoagglutinins is especially worrisome • Leukoagglutinins may stimulate active neutrophil aggregation

  32. Pathophysiology of TRALI • Activated neutrophils are sequestered in the microvasculature of the lungs • Production of bioactive products • ROS • Enzymes • Endothelial damage • Exudation of fluid and neutrophils into alveoli • Respiratory compromise

  33. Pathophysiology of TRALI • Exudative (high protein) fluid in alveoli • TACO has transudative (low protein) protein in alveoli • Damage to the pulmonary capillary endothelium leads to leakage into alveoli • Due to activated neutrophils damaging endothelium

  34. Pathophysiology of TRALI • Presence of HLA-antibodies and HNA antibodies in a blood product does not necessarily mean that these antibodies will cause TRALI • Cognate antigens in recipient may be necessary

  35. HLA and HNA antibodies • HLA antibodies identified in 70-75% of all TRALI cases • 85-90% antibody in transfused product • 10% in recipient • Rare inter-donor cases • antibody in transfused product directed against antigen in other transfused product • HNA antibodies 10-15% • 10-15% ? ?

  36. HLA and HNA antibodies Reil A, et al. VoxSanguinis 2008;95(4):313-317

  37. HLA and HNA antibodies • HNA-3a antibodies in 6 of 10 fatal cases in this study • Remainder were HLA Class II and HNA-2a

  38. HLA testing • All test rely on the AHG test • Plasma or serum is reacted to test antigens • Wash unbound antibody away • Incubate with anti-IgG • Wash unbound anti-IgG away • Detection

  39. HLA testing • Complement Dependent Cytotoxicity • Live cells • Mix with complement • Count living cells (dye exclusion) • Very labor intensive • Least sensitive • Cellular test • Not specific for HLA antibodies

  40. HLA testing • ELISA • Full range of antigens bound to test wells • Usually one well for Class I and one well for Class II • Less sensitive • Manual testing currently • automation under development • Acellular (specific for HLA antibodies) • No indeterminant tests: cutoff value

  41. HLA testing • Flow Cytometry • Latex microparticle beads with antigen • Complex test that is labor intensive • Indeterminate results possible • Acellular • Can distinguish between class I and class II due to differences in luminescence markers • Single run tests for both

  42. HLA testing • Luminex • Similar to Flow cytometry • Antigen coated microbeads • Fluorescent-tagged antibodies • Simpler chemiluminescence test • Instrument is smaller • Less expertise to operate • Both class I and class II can be simultaneously tested • Manual test, but automation looks easiest • No indeterminate tests…cutoff value

  43. HNA testing • Expensive ($200-300) , few labs doing this at the moment • Generally tests are labor-intensive and require high level of expertise to perform

  44. HNA testing • Granulocyte agglutination testing • Serum incubated for 4-6 hours with fresh neutrophils • Presence of antibodies cause clumping of neutrophils • Least sensitive of tests

  45. HNA testing • Granulocyte immunofluorescence (GIF) • Similar to AHG test • Pretreatment with 1% paraformaldehyde to prevent antibody binding to Fc portion of neutrophil receptor • Microscopy: Can have high background fluorescence making it difficult to read weak results • Flow cytometer is most often used now

  46. I got a TRALI case! What do I do now?

  47. Tenth Law of the House of God IF YOU DON’T TAKE A TEMPERATURE, YOU CAN’T FIND A FEVER. -- Samuel Shem (1978)

  48. Investigation of Suspected TRALI • Increased numbers of reported TRALI fatalities in past few years is due in large part to increased awareness on part of the folks at the bedside • Education of clinical personnel about TRALI recognition is critical. • CCC criteria • NHLBI WG criteria

More Related